NORTH CAROLINA CENTRAL UNIV has a total of 15 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 1990. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are CHONGQING ZHIEN PHARMACEUTICAL CO LTD, ALEMBIC PHARMACEUTICALS LTD and JIANGSU YUEXING PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Canada | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Biotechnology | |
#5 | Macromolecular chemistry and polymers | |
#6 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Yeh Li-An | 4 |
#2 | Williams Alfred L | 4 |
#3 | Taylor Darlene K | 3 |
#4 | Balami Uddhav | 3 |
#5 | Sexton Jonathan Z | 3 |
#6 | Scott John E | 3 |
#7 | Brenman Jay E | 3 |
#8 | Lopez Dayami | 2 |
#9 | Redinbo Matthew | 2 |
#10 | Hall Iris H | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020051370A1 | Discovery of novel potent inhibitors of the map3k mekk2 | |
EP3630157A1 | Optimization of an active pcsk9 assay | |
US2016289350A1 | Electroresponsive technology | |
EP3033083A1 | A high-throughput assay for identifying small molecules that modulate amp-activated protein kinase (ampk) | |
US2016046560A1 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | |
US5192761A | 1,2,4-triazolidine-3,5-diones and 1,3,5-triazine-2,4(1-H,3H)-diones, pharmaceutical compositions | |
US4999366A | Isoxazolidine-3,5-diones, pharmaceutical compositions and method of treatment |